サトウ カヨコ   SATO Kayoko
  佐藤 加代子
   所属   医学部 医学科(東京女子医科大学病院)
   職種   准教授
論文種別 原著
言語種別 英語
査読の有無 査読あり
表題 Statement for Appropriate Clinical Use of PCSK9 Inhibitors.
掲載誌名 正式名:Journal of atherosclerosis and thrombosis
略  称:J Atheroscler Thromb
ISSNコード:1340-3478/1880-3873
掲載区分国内
出版社 Japan Atherosclerosis Society
巻・号・頁 25(8),747-750頁
著者・共著者 Nohara Atsushi, Ohmura Hirotoshi, Okazaki Hiroaki, Ogura Masatsune, Kitagawa Kazuo, Koseki Masahiro, Sato Kayoko, Tsukamoto Kazuhisa, Yamashita Shizuya, On behalf of the Japan Atherosclerosis Society Working Group on Statement for Appropriate Use of PCSK9 Inhibitors
発行年月 2018/08
概要 PCSK9 inhibitors should be used for secondary prevention in patients with coronary artery disease when LDL-C management targets are not achieved with treatment combining ezetimibe and statins at the maximum tolerated dose, who include many FH heterozygotes. We have described the types of patients who would receive great benefit from PCSK9 inhibitors from the viewpoints of medical and medical economics at the present time and provided flowcharts for LDL-C lowering therapy including PCSK9 inhibitors. In initiating or continuing PCSK9 inhibitors, attention should be paid to the latest information and an experienced specialist should be consulted when necessary.
DOI 10.5551/jat.45229
PMID 29899173